Zobrazeno 1 - 10
of 11
pro vyhledávání: '"R M, O'Regan"'
Autor:
R M, O'Regan, A, Cisneros, G M, England, J I, MacGregor, H D, Muenzner, V J, Assikis, M M, Bilimoria, M, Piette, Y P, Dragan, H C, Pitot, R, Chatterton, V C, Jordan
Publikováno v:
JNCI Journal of the National Cancer Institute. 90:1552-1558
Background Tamoxifen has been shown to promote the growth of human endometrial tumors implanted in athymic mice, and it has been associated with a twofold to threefold increase in endometrial cancer. Toremifene, a chlorinated derivative of tamoxifen,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5113053f0e2b383e004dfd92452299a3
https://doi.org/10.1093/jnci/90.20.1552
https://doi.org/10.1093/jnci/90.20.1552
Autor:
F R Khuri, R M O'Regan
Publikováno v:
Endocrine-related cancer. 11(2)
The ras family of proto-oncogenes are upstream mediators of several essential cellular signal transduction pathways involved in cell proliferation and survival. Point mutations of ras oncogenes result in constitutively active Ras and have been shown
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db20acaa4706fc9f52de8dd61149568e
https://pubmed.ncbi.nlm.nih.gov/15163298
https://pubmed.ncbi.nlm.nih.gov/15163298
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 7(12)
Arzoxifene (Arzox) is a novel benzothiophene analogue with selective estrogen receptor modulator activity similar to raloxifene. Arzox is being developed as a treatment for breast cancer and has a predominantly antiestrogenic effect on the rodent ute
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0f94adeaa20f8da879434a12539481f3
https://pubmed.ncbi.nlm.nih.gov/11751515
https://pubmed.ncbi.nlm.nih.gov/11751515
Autor:
R M, O'Regan, W J, Gradishar
Publikováno v:
Oncology (Williston Park, N.Y.). 15(9)
Tamoxifen (Nolvadex), a selective estrogen-receptor modulator, or SERM, is currently the endocrine therapy of choice for all stages of hormone-responsive breast cancer. Only tamoxifen has been approved by the US Food and Drug Administration to reduce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2196922e3e71d160f40348388f6656fa
https://pubmed.ncbi.nlm.nih.gov/11589065
https://pubmed.ncbi.nlm.nih.gov/11589065
Autor:
R M, O'Regan, V C, Jordan
Publikováno v:
Cancer treatment and research. 106
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::96e3f95229be0b5c33e92b663bdf859b
https://pubmed.ncbi.nlm.nih.gov/11225001
https://pubmed.ncbi.nlm.nih.gov/11225001
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 6(12)
The triphenylethylene antiestrogens, idoxifene (Idox) and toremifene (Tor), are structurally related analogues of tamoxifen (Tam) and were developed to improve the therapeutic index for advanced breast cancer patients. However, the issue of cross-res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b03bebf22d19b70103cdee6d49e470c2
https://pubmed.ncbi.nlm.nih.gov/11156249
https://pubmed.ncbi.nlm.nih.gov/11156249
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 6(11)
MCF-7 cells are used routinely to study tamoxifen-stimulated drug resistance in vivo. However, unlike MCF-7 cells, T47D cells express mutant p53 protein and lose the estrogen receptor (ER) during long-term estrogen deprivation in vitro [Pink et al.,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8d110fa31a4753249157310b31532c13
https://pubmed.ncbi.nlm.nih.gov/11106256
https://pubmed.ncbi.nlm.nih.gov/11106256
Autor:
R M, O'Regan
Publikováno v:
Cancer treatment and research. 103
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d1de624222eb73f59a5c3e1adedbd4cd
https://pubmed.ncbi.nlm.nih.gov/10948447
https://pubmed.ncbi.nlm.nih.gov/10948447
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 6(5)
The estrogen receptor (ER)-positive MCF-7 breast cancer cell line can be transplanted into athymic mice and grown into tumors with estradiol (E2) support. Tamoxifen (TAM) blocks E2-stimulated tumor growth; however, continuous TAM treatment results in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3d7a38f40c56477fc61310755d1f74f6
https://pubmed.ncbi.nlm.nih.gov/10815929
https://pubmed.ncbi.nlm.nih.gov/10815929
Autor:
R. M. O'Regan, V. C. Jordan
Publikováno v:
JNCI Journal of the National Cancer Institute. 91:722-723
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f64e19a6083c21b8749dc233f33ad3d
https://doi.org/10.1093/jnci/91.8.722a
https://doi.org/10.1093/jnci/91.8.722a